Natera (NTRA) Stock Price, News & Analysis

Company Overview

Natera, Inc. is a global molecular diagnostics company headquartered in San Carlos, California. Founded in 2004 by Matthew Rabinowitz and Jonathan Sheena, the company specializes in developing and commercializing non-invasive genetic testing technologies. Natera’s platform leverages proprietary DNA analysis and bioinformatics to deliver insights across reproductive health, oncology and organ transplantation without the need for invasive procedures.

In the reproductive health arena, Natera’s flagship product is the Panorama™ non-invasive prenatal test (NIPT), which screens for fetal chromosomal abnormalities as early as ten weeks into pregnancy. The company also offers Horizon™ carrier screening for inherited single-gene disorders, enabling prospective parents to understand their genetic risk prior to conception or early in gestation.

Within oncology, Natera markets Signatera™, a personalized circulating tumor DNA (ctDNA) assay designed to detect minimal residual disease (MRD) and monitor treatment response in a variety of cancers. For organ transplantation, the Prospera™ assay quantifies donor-derived cell-free DNA to assess the risk of graft rejection. These tests aim to provide clinicians with actionable data to guide patient management and therapeutic decisions.

Natera went public on the Nasdaq stock exchange in December 2015 and has since expanded its testing services into Europe, Asia-Pacific and Latin America. Its centralized laboratories and global partnerships support thousands of healthcare providers and research institutions. The company continues to invest in R&D to enhance its genomics platform under the leadership of founder and Chief Scientific Officer Matthew Rabinowitz and an experienced executive team.

Key Stats

• Today's Range: $191.75 to $198.99
• 50-Day Range: $160.12 to $195.00
• 52-Week Range: $117.27 to $198.99
• Volume: 1.09 million shs
• Average Volume: 1.14 million shs
• Market Capitalization: $26.42 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $197.59
• Consensus Rating: Moderate Buy

Natera Stock Analysis - MarketRank™

Natera scored higher than 37% of companies evaluated by MarketBeat, and ranked 721st out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.6 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Natera has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 16 buy ratings, 1 hold rating, and 2 sell ratings.

Upside/Downside

The consensus price target for Natera is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Natera has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Natera are expected to grow in the coming year, from ($1.49) to ($1.25) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Natera is -100.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Natera is -100.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Natera has a P/B Ratio of 21.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

3.97% of the outstanding shares of Natera have been sold short.

Short Interest Ratio / Days to Cover

Natera has a short interest ratio ("days to cover") of 4.3.

Change versus previous month

Short interest in Natera has recently increased by 43.80%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Natera does not currently pay a dividend.

Dividend Growth

Natera does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.97% of the outstanding shares of Natera have been sold short.

Short Interest Ratio / Days to Cover

Natera has a short interest ratio ("days to cover") of 4.3.

Change versus previous month

Short interest in Natera has recently increased by 43.80%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.57

News Sentiment

Natera has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.93 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 36 news articles for Natera this week, compared to 20 articles on an average week.

Search Interest

11 people have searched for NTRA on MarketBeat in the last 30 days. This is an increase of 22% compared to the previous 30 days.

MarketBeat Follows

17 people have added Natera to their MarketBeat watchlist in the last 30 days. This is an increase of 750% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Natera insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $11,207,899.00 in company stock.

Percentage Held by Insiders

Only 5.63% of the stock of Natera is held by insiders.

Percentage Held by Institutions

99.90% of the stock of Natera is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

NTRA Stock Analysis - Frequently Asked Questions

How have NTRA shares performed this year?

Natera's stock was trading at $158.30 at the start of the year. Since then, NTRA stock has increased by 21.6% and is now trading at $192.51.

How were Natera's earnings last quarter?

Natera, Inc. (NASDAQ:NTRA) announced its quarterly earnings data on Thursday, August, 7th. The medical research company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.60) by $0.14. The business's revenue for the quarter was up 32.2% on a year-over-year basis.
Read the conference call transcript.

When did Natera IPO?

Natera (NTRA) raised $101 million in an IPO on Thursday, July 2nd 2015. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers.

Who are Natera's major shareholders?

Top institutional shareholders of Natera include Allspring Global Investments Holdings LLC (0.35%), Zevenbergen Capital Investments LLC (0.29%), Voya Investment Management LLC (0.26%) and Ninety One UK Ltd (0.25%). Insiders that own company stock include Roelof Botha, Matthew Rabinowitz, Daniel Rabinowitz, Steven Leonard Chapman, John Fesko, Solomon Moshkevich, Michael Burkes Brophy, Herm Rosenman, Jonathan Sheena, James Healy, Rowan E Chapman, Gail Boxer Marcus and Robert Alan Schueren.
View institutional ownership trends.

How do I buy shares of Natera?

Shares of NTRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Natera own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Natera investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AUO (AUOTY).

Company Calendar

• Last Earnings: 8/07/2025
• Today: 10/25/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:NTRA
• CIK: 1604821
• Web: www.natera.com
• Phone: (650) 249-9090
• Fax: N/A
• Employees: 4,434
• Year Founded: 2004

Price Target and Rating

• Average Price Target for Natera: $197.59
• High Price Target: $268.00
• Low Price Target: $157.00
• Potential Upside/Downside: +2.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 20 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.91)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$190.43 million
• Net Margins: -12.89%
• Pretax Margin: -12.90%
• Return on Equity: -22.22%
• Return on Assets: -15.03%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.72
• Quick Ratio: 3.58

Sales & Book Value

• Annual Sales: $1.70 billion
• Price / Sales: 15.57
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $9.05 per share
• Price / Book: 21.27

Miscellaneous

• Outstanding Shares: 137,250,000
• Free Float: 129,521,000
• Market Cap: $26.42 billion
• Optionable: Optionable
• Beta: 1.74